Sodium-glucose Cotransporter-2 Inhibitors for Heart Failure

Lau, Y. T., Cheng, H. S., & Hsieh, C. C. (1992). Sodium Transport in Hypertension. The Chinese Journal of Physiology, 35(3), 241-256. https://www.airitilibrary.com/Article/Detail?DocID=03044920-199209-35-3-241-256-a
陳宣雅（2015）。A Novel Therapeutic Agent for Type 2 Diabetes Mellitus: SGLT2 Inhibitor。台灣醫學，19(6)，636-642。https://doi.org/10.6320/FJM.2015.19(6).12
陳明德（2000）。Type 4 Glucose Transporter。台灣醫學，4(4)，431-433。https://doi.org/10.6320/FJM.2000.4(4).10
Wang, B. M., Kuo, F. J., & Huang, K. C. (2019). Control of Blood Glucose with Sodium Glucose Co-transporter 2 (SGLT2) Inhibitors Among Patients with Type 2 Diabetes Mellitus. Formosan Journal of Endocrinology and Metabolism, 10(), 1-6. https://doi.org/10.6856/FJEM.201912_10.0001
Tseng, K. B. (2021). Impact on Cardiovascular Disease of Sodium-Glucose Cotransporter-2 Inhibitors for the Treatment of Type 2 Diabetes: Where are We Now and What can We Expect?. 內科學誌, 32(4), 242-256. https://doi.org/10.6314/JIMT.202108_32(4).03